Market Place
Sourcing Support
Servier Presents Hematology Data at ASH Annual Meeting 2024
13 Nov 2024 //
PR NEWSWIRE
US FDA approves Servier`s brain tumor treatment
07 Aug 2024 //
PR NEWSWIRE
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
30 May 2024 //
PR NEWSWIRE
Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024
23 May 2024 //
PR NEWSWIRE
Servier Ranks 1st Across Categories In US PatientView Reputation Survey
14 May 2024 //
PR NEWSWIRE
New name takes top spot in US patient group reputation ranking
14 May 2024 //
FIERCE PHARMA
An Indian industrialist wants to buy Biogaran, the French number one in generics
18 Apr 2024 //
20MINUTES
InnONE presentation with Pascal Baraffe, General Manager in Arklow site
09 Apr 2024 //
PRESS RELEASE
Servier Data Presented at AACR
08 Apr 2024 //
PR NEWSWIRE
InnONE presentation with Pascal Baraffe, General Manager in Arklow site
07 Apr 2024 //
PRESS RELEASE
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib
21 Feb 2024 //
PR NEWSWIRE
FDA and EMA Accept Vorasidenib Regulatory Submissions for diffuse glioma
20 Feb 2024 //
PR NEWSWIRE
Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development
05 Jan 2024 //
PR NEWSWIRE
French drugmaker Servier ordered to pay $471 million for Mediator scandal
21 Dec 2023 //
REUTERS
Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition
09 Dec 2023 //
PR NEWSWIRE
Servier Data at ASH 2023 Furthers Leadership in Hematologic Malignancies
05 Dec 2023 //
PR NEWSWIRE
Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib`s Potential
18 Nov 2023 //
PR NEWSWIRE
Vorasidenib Data at SNO Bolster Servier`s Neuro-Oncology Development Program
10 Nov 2023 //
PR NEWSWIRE
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for MDS
24 Oct 2023 //
PR NEWSWIRE
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO
15 Aug 2023 //
PR NEWSWIRE
Servier Presents Results for TIBSOVO in IDH1-mutated Myelodysplastic Syndromes
09 Jun 2023 //
PR NEWSWIRE
Servier Bolsters Position as the Leader in Mutant IDH Inhibition at ASCO
05 Jun 2023 //
PR NEWSWIRE
Servier Presents Transformational Data from Phase 3 INDIGO Trial of Vorasidenib
04 Jun 2023 //
PR NEWSWIRE
Aitia Enters into Simulation Collaboration with Servier for Pancreatic Cancer
17 May 2023 //
PR NEWSWIRE
Servier’s Tibsovo receives marketing approval from EC to treat cancer
11 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) i
10 May 2023 //
PR NEWSWIRE
Taiho Oncology & Servier Announce in New Engl& Journal pH 3 Data for (LONSURF®)
03 May 2023 //
BUSINESSWIRE
Changes to the Executive Committee of Servier Group
26 Apr 2023 //
PRESS RELEASE
Servier’s 2023 Golden Ticket at LabCentral for Hovana, Inc.
24 Apr 2023 //
PRESS RELEASE
Mécénat Servier’s 2021/2022 Annual Report is now available!
07 Apr 2023 //
PRESS RELEASE
Specifica Announces Agreement with Servier and its Subsidiary Symphogen
29 Mar 2023 //
PRESS RELEASE
OMRON Healthcare and Servier announce a long-term strategic partnership
15 Mar 2023 //
PRESS RELEASE
Servier’s $1.8B bet on Agios delivers phase 3 brain tumor win
15 Mar 2023 //
FIERCE BIOTECH
Servier`s PIII INDIGO Trial Investigating vorasidenib Meets Primary Endpoint
14 Mar 2023 //
PR NEWSWIRE
For the first time, Servier is publishing an Integrated Annual Report
10 Mar 2023 //
PRESS RELEASE
Servier Announces Partnership with QIAGEN to Develop mIDH1 Diagnostic Test
09 Mar 2023 //
PR NEWSWIRE
Servier receives a positive CHMP opinion for Tibsovo in IDH1-mutated AML and CCA
24 Feb 2023 //
PR NEWSWIRE
Servier full year 2021/22 results confirm the transformation trajectory of Group
02 Feb 2023 //
PR NEWSWIRE
Servier & Taiho Present Survival Data for LONSURF With Bevacizumab at 2023 ASCO
17 Jan 2023 //
BUSINESSWIRE
Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology
09 Jan 2023 //
BUSINESSWIRE
Analysis Suggest Pediatric-Inspired Regimens Lead to Higher Survival in Patient
12 Dec 2022 //
PRNEWSWIRE
Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
10 Dec 2022 //
PRNEWSWIRE
Rigel wins US approval of rival drug to Servier leukemia treatment
03 Dec 2022 //
BIOPHARMADIVE
Saclay-Boston Masterclass Season 2: 7 start-up are going to discover paragon
07 Nov 2022 //
PRESS RELEASE
Primary Sjögren’s syndrome: completion of patient enrollment in Phase 2a trial
03 Nov 2022 //
PRESS RELEASE
Servier at ASH meeting to present new data in hematology research
03 Nov 2022 //
PRESS RELEASE
New Data at ASH 2022 Bolster Servier`s Leadership in Hematology Research
03 Nov 2022 //
PRNEWSWIRE
Servier &OSE Announce Completion of Enrollment in Ph2a Trial of OSE-127/S95011
02 Nov 2022 //
PHARMIWEB
In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo
28 Oct 2022 //
ENDPTS
Servier & HealthTech For Care, a commitment to accelerate therapeutic innovation
12 Oct 2022 //
PRESS RELEASE
Servier unveils its 2030 ambition and reveals a new visual identity
06 Oct 2022 //
PRESS RELEASE
Servier exercises licensing option on collaborative program with Precision
26 Sep 2022 //
PRESS RELEASE
Servier severs CAR-T collab with Allogene
23 Sep 2022 //
FIERCEBIOTECH
Servier is boosting its digital transformation with Google Cloud!
22 Sep 2022 //
PRESS RELEASE
Servier collaborates in the treatment of pancreatic cancer
22 Sep 2022 //
PRESS RELEASE
Servier cuts off collaboration agreement with Allogene on CD19 products
21 Sep 2022 //
ENDPTS
Servier backs a startup research project to accelerate therapeutic innovation
16 Sep 2022 //
PRESS RELEASE
Servier leverages Mission Bio`s Tapestri Platform to uncover AML resistance
15 Sep 2022 //
APNEWS
Drug Combination Meets Survival Endpoint in Ph III Pivotal Trial With RMCC
12 Sep 2022 //
BUSINESSWIRE
